ALX Oncology Shakes Up Leadership Ahead of Critical Pipeline Milestones
Event summary
- ALX Oncology appoints Scott Garland as Chairman of the Board, replacing co-founder Corey Goodman after over a decade of leadership.
- Michael Listgarten joins as General Counsel, bringing 30 years of biopharmaceutical legal experience.
- Garland has served on ALX Oncology's board since November 2022, with extensive commercial and operational expertise.
- Listgarten previously held senior legal roles at RAPT Therapeutics, Adamas Pharmaceuticals, and Genentech.
The big picture
ALX Oncology's leadership overhaul comes as it prepares for pivotal milestones in its immuno-oncology pipeline. The appointments of Garland and Listgarten signal a shift toward commercialization-ready governance, aligning with broader industry trends where seasoned executives are brought in to navigate late-stage clinical development and potential regulatory hurdles. The move underscores the company’s focus on sustaining momentum as it approaches critical inflection points for its lead candidates.
What we're watching
- Pipeline Progress
- How the new leadership will impact the advancement of evorpacept into registration studies and ALX2004's Phase 1 trial.
- Strategic Partnerships
- Whether Listgarten’s experience can deepen ALX Oncology’s strategic partnerships during critical inflection points.
- Governance Dynamics
- The pace at which Garland transitions the company from foundational leadership to scalable growth.
Related topics